Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Visionary Venture Fund

Investor type Micro VC
Founders Ehsan Sadri

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 17
Average round size
info
The average size of a deal this fund participated in
$23M
Portfolio companies 13
Rounds per year 2.83
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.24
Exits 3
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Medical Device
  • Biotechnology
  • Pharmaceutical
  • Medical
Summary

The company was established in North America in United States. The leading representative office of defined VC is situated in the Aliso Viejo.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 25 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. The fund is constantly included in 2-6 deals per year. The top amount of exits for fund were in 2018. This Visionary Venture Fund works on 11 percentage points less the average amount of lead investments comparing to the other organizations.

The usual cause for the fund is to invest in rounds with 2 partakers. Despite the Visionary Venture Fund, startups are often financed by Tigris Ventures, Sequoia Capital Israel, Flying L Partners. The meaningful sponsors for the fund in investment in the same round are Flying L Partners, Bluestem Capital, Vivo Capital. In the next rounds fund is usually obtained by Petrichor Healthcare Capital Management, Global Health Investment Fund (GHIF), Flying L Partners.

Among the most popular portfolio startups of the fund, we may highlight CorneaGen, Mynosys, Iantech. The fund has exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Chemical Engineering, Pharmaceutical.

The current fund was established by Ehsan Sadri.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Visionary Venture Fund:
Typical Co-investors
Visionary Venture Fund is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Visionary Venture Fund:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bayerische Motoren Werke Bayern, Germany, Munich
Bitfury Group Amsterdam, Noord-Holland, The Netherlands
Burch Investment Group Nashville, Tennessee, United States
Digital Ventures Australia, Perth, Western Australia
F&G Venture China, Shanghai, Shanghai
Gibraltar Business Capital Illinois, Northbrook, United States
Holdinvest Argentina, Buenos Aires, Distrito Federal
Jianyin International Capital Management -
Jiasufei Keji Beijing, China, Haidian
New Harbor Capital Chicago, Illinois, United States
NextWaveBio Connecticut, East Hartford, United States
Qingdao Citymedia Co. China, Qingdao Shi, Shandong
RITEK Corporation China, Jiangsu, Taiwan
Rosalind Advisors -
Saichen Jisheng China, Hangzhou, Zhejiang
SANAD Fund Frankfurt, Germany, Hessen
Sukna Ventures Ar Riyad, Riyadh, Saudi Arabia
Thinktiv Austin, Texas, United States
Visma Norway, Oslo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Aurion Biotechnologies

Biotechnology
$120M12 Apr 2022 Seattle, Washington, United States

Sydnexis

Manufacturing
Pharmaceutical
$45M10 Aug 2021 California, United States

Orasis Pharmaceuticals

Clinical Trials
Health Care
Medical
Pharmaceutical
$30M10 Sep 2020 Israel, Tel Aviv District, Israel

TearClear

Chemical Engineering
Medical Device
Pharmaceutical
$22M11 Aug 2020 Boston, Massachusetts, United States

Re-Vana Therapeutics

Health Care
Market Research
Medical
Therapeutics
$3M02 Jun 2020 Northern Ireland

Tarsus Pharmaceuticals

Biopharma
Biotechnology
Life Science
$60M08 Jan 2020 Irvine, California, United States

Biopharma
Health Care
Pharmaceutical
$21M11 Jul 2018 California, United States

Orasis Pharmaceuticals

Clinical Trials
Health Care
Medical
Pharmaceutical
$13M05 Jun 2018 Israel, Tel Aviv District, Israel

Tear Film Innovations

Health Care
Medical
Medical Device
$8M23 May 2018 Carlsbad, California, United States
News
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Visionary Venture Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: